Office of Imran Amir, MD, FAAD

Eczema and Skin Allergy Center

Enhance your natural beauty and overall skin health at City Dermatology.
  • What is Atopic Dermatitis?
    • A chronic inflammatory skin condition characterized by itchy, red, and dry patches.
    • Commonly seen in children but can affect people of all ages; often associated with a personal or family history of allergies, asthma, or hay fever.
    • Typically presents in cycles of flare-ups and remissions.
  • Skin Changes:
    • Red, inflamed patches that are dry and scaly; can become thickened (lichenified) due to chronic scratching.
    • May ooze or form crusts if infected.
  • Location:
    • Commonly affects the face, elbows, knees, and hands in children.
    • In adults, can occur in flexural areas (inside of elbows and knees), neck, hands, and around eyes.
  • Intense Itching:
    • Itching is often severe, worse at night, and can interfere with sleep.
    • Scratching can further damage the skin and lead to infection or worsening of symptoms.
  • Genetic Factors:
    • A family history of atopic diseases (eczema, asthma, hay fever) increases the risk.
  • Immune System Dysfunction:
    • Overreactive immune response leads to inflammation and skin barrier dysfunction.
  • Skin Barrier Defects:
    • A compromised skin barrier leads to dryness and makes the skin more susceptible to irritants and allergens.
  • Common Triggers:
    • Environmental factors like allergens (dust, pollen), irritants (soaps, detergents), heat, sweat, stress, and certain foods.
  • Clinical Examination:
    • Diagnosed based on appearance, symptoms, and medical history.
  • Allergy Testing:
    • In some cases, allergy tests (skin prick tests or blood tests) may help identify specific triggers.
  • Skin Moisturization:
    • Use thick, fragrance-free emollients or creams regularly to maintain skin hydration.
    • Apply immediately after bathing to lock in moisture.
  • Topical Corticosteroids:
    • Anti-inflammatory creams or ointments to reduce redness and itching during flares.
    • Vary in strength from mild to potent, depending on severity and location.
  • Topical Calcineurin Inhibitors:
    • Non-steroidal anti-inflammatory creams (tacrolimus, pimecrolimus) used for sensitive areas or long-term management.
  • Oral Medications:
    • Antihistamines to relieve itching and improve sleep.
    • Short-term use of oral corticosteroids for severe flare-ups.
  • Immunotherapy and Biologics:
    • Dupilumab (a monoclonal antibody) for moderate to severe cases not responding to other treatments.
  • Lifestyle and Trigger Management:
    • Identify and avoid known triggers (e.g., allergens, stress).
    • Use gentle, hypoallergenic skincare products and detergents.
  • Infections:
    • Skin is more prone to bacterial, viral (e.g., herpes simplex), and fungal infections due to scratching and open sores.
  • Sleep Disturbance:
    • Persistent itching can disrupt sleep and lead to daytime fatigue.
  • Impact on Quality of Life:
    • Can affect self-esteem, mental health, and daily activities, especially in children.
  • Chronic Condition:
    • Eczema often improves with age; many children outgrow it by adolescence.
    • Some people may continue to experience symptoms into adulthood.
  • Management:
    • No cure, but symptoms can be well-controlled with proper skincare, trigger avoidance, and appropriate treatment.
  • Prevention:
    • Maintaining skin moisture and avoiding irritants can help prevent flare-ups and reduce the severity of symptoms.

Current Treatments of Atopic Dernatitis

Treatment for atopic dermatitis aims to control symptoms, reduce inflammation, and prevent flare-ups. Regular moisturization is essential to keep the skin barrier intact and to reduce dryness and itching. Topical corticosteroids are commonly prescribed to reduce inflammation during flare-ups, and their potency can be adjusted based on the severity of the condition. Topical calcineurin inhibitors, such as tacrolimus and pimecrolimus, are steroid-free options used for sensitive areas like the face or for longer-term management. For more moderate to severe cases, phototherapy (light therapy) or systemic medications like oral corticosteroids, cyclosporine, methotrexate, and biologics (e.g., dupilumab) may be recommended to control the immune response and inflammation. Newer treatments like JAK inhibitors have also shown promise in reducing inflammation and itchiness. Lifestyle measures such as avoiding triggers (like certain soaps, fabrics, or allergens), reducing stress, and using gentle skincare routines are also key components of managing atopic dermatitis effectively.

Recent advancements in the treatment of atopic dermatitis (AD) have introduced newer biologic therapies, offering targeted options for patients with moderate to severe disease who may not respond well to traditional treatments. These biologics work by inhibiting specific pathways in the immune system that drive inflammation and skin symptoms. Below are some of the newer biologic treatments and their associated side effects.

  1. Dupilumab (IL-4/IL-13 Inhibitor)
    Dupilumab is the first and most widely used biologic for atopic dermatitis. It works by blocking the action of interleukin-4 (IL-4) and interleukin-13 (IL-13), key cytokines involved in the inflammatory process of AD. Dupilumab has been effective in reducing itching, inflammation, and improving overall skin condition.
    • Common Side Effects: Conjunctivitis (eye inflammation), injection site reactions, cold sores (oral herpes), and eye or eyelid inflammation.
    • Rare Side Effects: Rarely, dupilumab can cause serious allergic reactions or worsen existing eye conditions like keratitis (inflammation of the cornea).
  2. Tralokinumab (IL-13 Inhibitor)
    Tralokinumab is a newer biologic that specifically targets IL-13, a cytokine known to play a major role in the pathophysiology of atopic dermatitis. It is effective in reducing skin inflammation and itch, with fewer effects on other immune pathways.
    • Common Side Effects: Injection site reactions, upper respiratory tract infections, eye inflammation (though less frequent than with dupilumab), and headache.
    • Rare Side Effects: Tralokinumab has a generally favorable safety profile, but there is still a risk of allergic reactions and increased susceptibility to infections.
  3. Lebrikizumab (IL-13 Inhibitor)
    Lebrikizumab is another biologic that targets IL-13 and has shown promise in clinical trials for reducing the symptoms of moderate to severe atopic dermatitis.
    • Common Side Effects: Injection site reactions, eye infections or inflammation, and headache.
    • Rare Side Effects: As with other biologics, there may be a risk of allergic reactions and increased risk of infections, though more long-term data are needed.

Although not technically biologics, JAK inhibitors like upadacitinib and abrocitinib are targeted oral medications that have been introduced for the treatment of moderate to severe atopic dermatitis. They work by interfering with the JAK-STAT pathway, which plays a key role in the inflammatory process.

  • Common Side Effects: Acne, nausea, headache, increased cholesterol levels, and increased risk of infections like upper respiratory tract infections.
  • Rare Side Effects: Serious infections, blood clots, and a potential increase in the risk of cardiovascular events or cancer, which necessitate careful monitoring during treatment.

While these newer biologic therapies offer more targeted treatment and often significant improvement in symptoms and quality of life for patients with atopic dermatitis, they come with their own set of potential side effects and risks. It’s important for patients to have ongoing monitoring for infections, eye problems, and any other signs of adverse reactions while on these treatments. A healthcare provider will help weigh the benefits against the risks based on an individual’s specific case and health history.

Visit Our Aesthetic Branch, Reimagine Aesthetics by Dr. Amir